己芴溴铵 | 317-52-2

• 分子结构分类: 有机化合物 - 有机氮化合物
• 中文名称: 己芴溴铵
• 英文名称: Hexafluorenium Bromide
• 英文别名: 9H-fluoren-9-yl-[6-[9H-fluoren-9-yl(dimethyl)azaniumyl]hexyl]-dimethylazanium;dibromide
• CAS: 317-52-2
• 化学式: C36H42Br2N2
• 分子量: 662.5
• InChiKey: WDEFPRUEZRUYNW-UHFFFAOYSA-L

物化性质

• 熔点：
  188-189°
• 密度：
  1.1954 (rough estimate)

计算性质

• 辛醇/水分配系数(LogP)：
  2.25
• 重原子数：
  40
• 可旋转键数：
  9
• 环数：
  6.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  0
• 氢给体数：
  0
• 氢受体数：
  2

安全信息

• 海关编码：
  2923900090

文献信息

• PRODRUG COMPOSITIONS, PRODRUG NANOPARTICLES, AND METHODS OF USE THEREOF
  申请人：Washington University

  公开号：US20160279060A1

  公开（公告）日：2016-09-29

  The present invention encompasses prodrug compositions, nanoparticles comprising one or more prodrugs, and methods of use thereof.

  本发明涵盖了前药组合物、包含一种或多种前药的纳米粒子，以及其使用方法。
• [EN] PRODRUG COMPOSITIONS AND METHODS OF TREATMENT<br/>[FR] COMPOSITIONS DE PROMÉDICAMENT ET PROCÉDÉS DE TRAITEMENT
  申请人：AQUESTIVE THERAPEUTICS INC

  公开号：WO2021087359A1

  公开（公告）日：2021-05-06

  Pharmaceutical compositions include a prodrug of epinephrine are described.

  药物组合物包括表述的肾上腺素前药。
• Multi-functional ionic liquid compositions for overcoming polymorphism and imparting improved properties for active pharmaceutical, biological, nutritional, and energetic ingredients
  申请人：Rogers D. Robin

  公开号：US20070093462A1

  公开（公告）日：2007-04-26

  Disclosed are ionic liquids and methods of preparing ionic liquid compositions of active pharmaceutical, biological, nutritional, and energetic ingredients. Also disclosed are methods of using the compositions described herein to overcome polymorphism, overcome solubility and delivery problems, to control release rates, add functionality, enhance efficacy (synergy), and improve ease of use and manufacture.

  揭示了离子液体及制备活性药物、生物、营养和能量成分的离子液体组合物的方法。还揭示了利用本文描述的组合物的方法，以克服多型性、克服溶解度和输送问题、控制释放速率、增加功能性、增强功效（协同作用）以及改善易用性和制造工艺。
• Physical, chemical, and isotopic (atomic) labels
  申请人：Pearl Technology Holdings, LLC.

  公开号：US20040258617A1

  公开（公告）日：2004-12-23

  Chemical or isotopic labels are added to, e.g., a potentially lethal drug formulation, to generate a unique chemical fingerprint. Combinations of chemical additives are mixed with the drug to aid in their isolation and identification, especially when such drugs are used for illicit purposes. When stable isotopes are incorporated into lethal drugs, the labeling process conveys a very unique internal chemical signature and greatly aids in the identification of the parent drug in body fluids and tissues. When heath-care providers become aware that certain drugs can now be easily tracked and identified in a victim, individuals may be reluctant to utilize these agents for ill purposes.

  化学或同位素标记被添加到例如潜在致命的药物配方中，以生成独特的化学指纹。化学添加剂的组合与药物混合在一起，以帮助其隔离和识别，尤其是当这些药物被用于非法目的时。当稳定同位素被纳入致命药物中时，标记过程传达了非常独特的内部化学签名，并极大地帮助在体液和组织中识别母药。当医疗保健提供者意识到某些药物现在可以轻松跟踪和识别受害者时，个人可能会不愿意将这些药物用于不良目的。
• Anticoagulant contrast media
  申请人：Melton J. Laura

  公开号：US20050281746A1

  公开（公告）日：2005-12-22

  The present invention provides novel anticoagulant contrast agents, which comprise an organic scaffolding moiety, an organic anticoagulant moiety, and an imaging moiety. The invention also provides anticoagulant contrast media and methods of visualizing internal structures utilizing the novel anticoagulant contrast agents and anticoagulant contrast media.

  本发明提供了一种新型抗凝对比剂，包括有机支架基团、有机抗凝基团和成像基团。该发明还提供了抗凝对比介质和利用新型抗凝对比剂和抗凝对比介质来可视化内部结构的方法。